key: cord-1022115-hmyjedqe
authors: Kashani, Kianoush B.
title: Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes
date: 2020-04-23
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.04.021
sha: 7a8673c2e3392a5ce60b39c72d1ddf535d4c82bc
doc_id: 1022115
cord_uid: hmyjedqe

nan

In December 2019, reports of an outbreak of an unusual viral pneumonia were released from Wuhan, China, which was later found to be due to infection with the novel SARS-CoV-2 virus. In the following months, this viral infection, as known as COVID-19, became a pandemic that now is engaging an ever-growing number of individuals across the globe, with a high rate of morbidity and mortality. COVID-19 not only has impacted healthcare systems at the global levels but also has led to a significant downturn in the world economy, both of which may increase the adverse effects of this infectious disease, particularly in resource-limited areas.

While the COVID-19 pandemic has led to many misfortunate life and livelihood losses, it has also resulted in solidarity at the global level in the patient care and instigated innovative approaches to prevent, manage, or treat this disease 1 .

There are several characteristics of COVID-19, which have caused considerable concerns. The patterns of transmission of this virus are progressively recognized. It appears that transmission of this virus is mostly via droplets unless infected individuals undergo aerosol-generating procedures that result in the airborne mode of transmission. Indeed, places that implemented social distancing, hand washing, and face masks as a priority have had success in controlling the spread of this virus. The other concern is that asymptomatic individuals could also shed the virus and thus contribute to its rapid spread in the communities 2 . Therefore, widespread testing and contact tracking of infected individuals could also result in a slower spread of this disease.

Large areas of uncertainty exist regarding COVID-19, and these include the extent of immunity after recovery from COVID-19, inherent and environmental risk factors of more severe illnesses, and a global or local consensus on preventive, management, or therapeutic options for COVID-19 1 .

One of the substantial challenges related to COVID-19 is the high incidence of multiorgan involvement when compared with other viral infections (i.e., lungs, heart, kidney, gastrointestinal, coagulation system 3 , etc.). However, it seems that the respiratory system is one of the most commonly engaged organs. COVID-19 pneumonia could lead to acute respiratory distress syndrome (ARDS), and the characteristics of COVID-19-associated ARDS may be similar or differ from those seen in ARDS due to other causes. Specifically, COVID-19associated ARDS engages older individuals and those with comorbid conditions (e.g., hypertension, diabetes mellitus) 4 ; is associated with significant dyspnea 4 ; it presents with different phenotypes (i.e., L vs. H phenotypes that differ by lung elastance, ventilation to perfusion ratio [V/Q], right-to-left shunt, and lung recruitability 5 ); it imposes hypoxia that could be due to high shunt physiology (i.e., hypoventilated areas of the lung are very hyperemic 6 particularly in H phenotype); patients so afflicted require a prolonged period to resolve their ARDS 7 ; and it has high mortality rates (51%) 4 . These patients frequently require a higher level of care in hospitals or intensive care units (ICU), and deescalation to a lower level of care or discharge may require several days. These factors have led to tremendous pressure on the healthcare systems, particularly in the COVID-19 hot-spots. The ability to triage patients who may need care levels escalation could not only assist with appropriate bed assignment and prevention of healthcare overflow, but it also can potentially improve patients' outcomes by earlier initiation of preventive and management measures. patients to a higher level of care; resources are thereby conserved and preventive and management measures more expeditiously initiated. Besides, these markers could be used to potentially enroll appropriate patients in much-needed clinical trials to find the proper treatment for this deadly disease.

While this paper is timely and adds significant value to the current and growing literature on the topic, there remain some unresolved questions that should be addressed in future investigations. The assessment of oxygen saturation in the arterial blood (PaO2) when it is estimated by pulse oximetry should be carefully interpreted. Estimated oxygen saturation by cooximeters (SpO2) could be different from measured arterial oxygen saturation by about ±4% 9 . Therefore, validating the results of Xie et al. findings by measured arterial oxygen saturation could be the next step. Furthermore, to be able to correctly assess the lung capacity for gas exchange, knowing the fraction of inspired oxygen (FiO2) is a necessity. Achieving this information may be challenging in some clinical scenarios. For example, the estimates of FiO2 when nasal cannula or face masks are used may be very variable (e.g., when 2 liters by nasal cannula is used, FiO2 could vary between 24-35% depending on the tidal volume patients demand) 9, 10 . Therefore, in the next models for prediction of mortality among patients with COVID-19, using the ratio between SPO2 or PaO2 and FiO2 may be necessary. It is also essential to assess the correlation between lung gas exchange capacity and mortality in light of different phenotypes of ARDS (i.e., L vs. H phenotypes). When V/Q mismatch drives hypoxia, the delivery of higher FiO2 leads to higher PaO2 and SpO2 (L phenotype). In contrast, when shunt drives the hypoxia, the impact of FiO2 on the improvement of oxygen saturation would be less evident 5, 6 .

Xie et al. also reported dyspnea as a significant predictor of mortality among COVID-19

patients. Dyspnea is defined as a subjective sense of breathlessness, and it is often mistaken with tachypnea, hyperpnea, or hyperventilation. Therefore, it is important that in future studies to assess this symptom more objectively. For example, describing its acuity, its presence at rest or exertion or in different positions, and its precipitating or alleviating factors may facilitate triage of these patients into a more appropriate level of care.

As our knowledge and understanding of COVID-19 and its pathophysiology progressively increase, the paper by Xie et al. represents remarkable progress in the field. In particular, this study links the outcomes of COVID-19-associated pneumonia with straightforward clinical signs and symptoms, linkage with a clear and plausible pathophysiologic basis.

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Spread of SARS-CoV-2 in the Icelandic Population

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive care medicine

Covid-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome. American journal of respiratory and critical care medicine

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Association Between Hypoxemia and Mortality in Patients With COVID-19

Basing Respiratory Management of Coronavirus on Physiological Principles. American journal of respiratory and critical care medicine

FiO2 in an Adult Model Simulating High-Flow Nasal Cannula Therapy